Brainsway Ltd
NASDAQ:BWAY

  • LAST PRICE
    9.9000
  • TODAY'S CHANGE (%)
    0.0600 (0.6098%)
  • Bid / Lots
    9.9000/ 1
  • Ask / Lots
    9.9600/ 6
  • Open / Previous Close
    9.8800 / 9.8400
  • Day Range
    9.5274
    9.9600
  • 52 Week Range
    4.6100
    10.9800
  • Volume
    18,316

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 20, 2024

      Show headlines and story abstract

    • 8:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
      Companies Mentioned: BWAY

      BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy

      Reductions also seen in comorbid anxiety and depression symptoms

      BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of positive feasibility clinical data evaluating the analgesic effects of deep transcranial magnetic stimulation (Deep TMS(TM)) in patients with peripheral neuropathic pain. The results were published in the Neuromodulation journal, in a peer-reviewed article entitled, "H-Coil Repetitive Transcranial Magnetic Stimulation Relieves Pain and Symptoms of Anxiety and Depression in Patients with Chronic Peripheral Neuropathic Pain: A Randomized Sham-Controlled Crossover Study."

  • Nov 12, 2024

      Show headlines and story abstract

    • 7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: BWAY
      trade receivables 415 (31) 295 1,404 Increase in inventory (465) (373) (572) (6) Decrease (increase) in other current assets 41 369 72 (243) Increase (decrease) in trade payables (366) (58) 514 (639) Increase (decrease) in other accounts payable 456 401 (74) (356) Increase (decrease) in deferred revenues and other liabilities (52) (173) 1,151 238 Total changes in asset and liability 29 135 1,386 398 ------ ------ ------ ------ Cash paid and received during the period for: Interest paid (81) (100) (104) (103) Interest received 613 546 2,194 1,586 Income taxes paid - - (994) (11) Total cash paid and received during the period 532 446 1,096 1,472 ------ ------ ------ ------ Net cash provided by (used in) operating activities: 2,278 1,356 6,804 (1,190) ------ ------ ------ ------ Cash flows from investing activities: Purchase of property and equipment and system components, net (1,300) (514) (2,871) (1,945) Proceeds from sub-lease asset - - 40 - Withdrawal of (investment in) deposits, net (34) 8 34,985 (8) Net cash provided by (used in) investing activities (1,334) (506) 32,154 (1,953) ------ ------ ------ ------ Cash flows from financing activities: Repayment of liability in respect of research and development grants (572) - (1,104) (345) Exercise of share options - - 19 - Receipt of government grants - - - 32 Repayment of lease liability (126) (56) (237) (186) Net cash used in financing activities (698) (56) (1,322) (499) ------ ------ ------ ------ Exchange rate differences on cash and cash equivalents 17 (69) (29) (46) ------ ------ ------ ------ Increase (decrease) in cash and cash equivalents 263 725 37,607 (3,688) Cash and cash equivalents at the beginning of the period 47,864 43,168 10,520 47,581 ------ ------ ------ ------ Cash and cash equivalents at the end of the period $ 48,127 $ 43,893 $ 48,127 $43,893 ====== ====== ====== ====== (a) Significant non cash transactions: Recognition of new lease liability and right-of-use $ 5,469 $ - $ 5,650 $ 207 ====== ====== ====== ====== Termination of lease liability and right-of-use $ - $ - $ 17 $ 70 ====== ====== ====== ====== BRAINSWAY LTD. A reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable IFRS measure, is set forth below: U.S. dollars in thousands (except share and per share data) For the three months ended For the nine months September 30, ended September 30, --------------- -------------------- 2024 2023 2024 2023 ----- ---- ----- ------ (Unaudited) (Unaudited) Net income (loss) and total comprehensive income (loss) $ 662 $(230) $1,373 $(4,324) Finance expense (income), net (456) 38 (763) (1,234) Income taxes 75 59 350 415 Depreciation and amortization 188 85 308 279 Depreciation of leased systems 260 247 755 719 Cost of share based payment 388 95 1,057 147 Restructuring and litigation Cost - 50 - 852 Adjusted EBITDA $1,117 $ 344 $3,080 $(3,146) ----- ---- -----

    • 7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: BWAY
      trade receivables 415 (31) 295 1,404 Increase in inventory (465) (373) (572) (6) Decrease (increase) in other current assets 41 369 72 (243) Increase (decrease) in trade payables (366) (58) 514 (639) Increase (decrease) in other accounts payable 456 401 (74) (356) Increase (decrease) in deferred revenues and other liabilities (52) (173) 1,151 238 Total changes in asset and liability 29 135 1,386 398 ------ ------ ------ ------ Cash paid and received during the period for: Interest paid (81) (100) (104) (103) Interest received 613 546 2,194 1,586 Income taxes paid - - (994) (11) Total cash paid and received during the period 532 446 1,096 1,472 ------ ------ ------ ------ Net cash provided by (used in) operating activities: 2,278 1,356 6,804 (1,190) ------ ------ ------ ------ Cash flows from investing activities: Purchase of property and equipment and system components, net (1,300) (514) (2,871) (1,945) Proceeds from sub-lease asset - - 40 - Withdrawal of (investment in) deposits, net (34) 8 34,985 (8) Net cash provided by (used in) investing activities (1,334) (506) 32,154 (1,953) ------ ------ ------ ------ Cash flows from financing activities: Repayment of liability in respect of research and development grants (572) - (1,104) (345) Exercise of share options - - 19 - Receipt of government grants - - - 32 Repayment of lease liability (126) (56) (237) (186) Net cash used in financing activities (698) (56) (1,322) (499) ------ ------ ------ ------ Exchange rate differences on cash and cash equivalents 17 (69) (29) (46) ------ ------ ------ ------ Increase (decrease) in cash and cash equivalents 263 725 37,607 (3,688) Cash and cash equivalents at the beginning of the period 47,864 43,168 10,520 47,581 ------ ------ ------ ------ Cash and cash equivalents at the end of the period $ 48,127 $ 43,893 $ 48,127 $43,893 ====== ====== ====== ====== (a) Significant non cash transactions: Recognition of new lease liability and right-of-use $ 5,469 $ - $ 5,650 $ 207 ====== ====== ====== ====== Termination of lease liability and right-of-use $ - $ - $ 17 $ 70 ====== ====== ====== ====== BRAINSWAY LTD. A reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable IFRS measure, is set forth below: U.S. dollars in thousands (except share and per share data) For the three months ended For the nine months September 30, ended September 30, --------------- -------------------- 2024 2023 2024 2023 ----- ---- ----- ------ (Unaudited) (Unaudited) Net income (loss) and total comprehensive income (loss) $ 662 $(230) $1,373 $(4,324) Finance expense (income), net (456) 38 (763) (1,234) Income taxes 75 59 350 415 Depreciation and amortization 188 85 308 279 Depreciation of leased systems 260 247 755 719 Cost of share based payment 388 95 1,057 147 Restructuring and litigation Cost - 50 - 852 Adjusted EBITDA $1,117 $ 344 $3,080 $(3,146) ----- ---- -----

  • Oct 29, 2024

      Show headlines and story abstract

    • 8:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
      Companies Mentioned: BWAY

      BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

      BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, November 12, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Peers Headlines